CoChat
Sign Up
Cited by 94Parkinson's Disease Mechanisms and TreatmentsCoenzyme Q10 studies and effectsNeurological Disorders and Treatments

Nicotinamide adenine dinucleotide (NADH) — a new therapeutic approach to Parkinson's disease: Comparison of oral and parenteral application

Birkmayer, J. G. D., Vrecko, C., Volc, D., Birkmayer, W.·1993·Acta Neurologica Scandinavica
DOI 10.1111/j.1600-0404.1993.tb00018.x
Open this paper in CoChat — free account

Abstract

The reduced coenzyme nicotinamide adenine dinucleotide (NADH) has been used as medication in 885 parkinsonian patients in an open label trial. About half of the patients received NADH by intravenous infusion, the other part orally by capsules. In about 80% of the patients a beneficial clinical effect was observed: 19.3% of the patients showed a very good (30-50%) improvement of disability, 58.8% a moderate (10-30%) improvement. 21.8% did not respond to NADH. Statistical analysis of the improvement in correlation with the disability prior to treatment, the duration of the disease and the age of the patients revealed the following results: All these 3 parameters have a significant although weak influence on the improvement. The disability before the treatment has a positive regression coefficient (t value < 0.01). The duration of the disease has a negative regression coefficient (< 0.01) and so has the age a negative regression coefficient (t value < 0.05). In other words younger patients and patients with a shorter duration of disease have a better chance to gain a marked improvement than older patients and patients with longer duration of the disease. The orally applied form of NADH yielded an overall improvement in the disability which was comparable to that of the parenterally applied form.

Integrity signals

Registry

Crossref · 10.1111/j.1600-0404.1993.tb00018.x

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • NADH has shown beneficial effects on movement in PD.

    “With relation to PD, NADH has shown beneficial effects on movement.”

    From NAD+ in Brain Aging and Neurodegenerative Disorders (2019) · cites this paper as Birkmayer et al., 1993

  • A later study with 885 PD patients confirmed similar benefits for parenteral and oral NADH.

    “The benefits were confirmed in a following study with 885 PD patients, also showing similar benefits between parenteral and oral applications”

    From NAD+ in Brain Aging and Neurodegenerative Disorders (2019) · cites this paper as Birkmayer et al., 1993

  • NAD+ depletion is reported in several models of accelerated ageing that exhibit neurodegeneration, as well as in neurodegenerative diseases including Alzheimer disease, Parkinson disease and amyotrophic lateral sclerosis.

    “NAD+ depletion is reported in several models of accelerated ageing which exhibit neurodegeneration33,134,135, as well as in neuro-degenerative diseases, including Alzheimer disease136, Parkinson disease137,138 and amyotrophic lateral sclerosis (ALS)139.”

    From NAD+ metabolism and its roles in cellular processes during ageing (2021) · cites this paper as [138]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Birkmayer, J. G. D., Vrecko, C., Volc, D., & Birkmayer, W.
Affiliations
  • Birkmayer‐Institut für Parkinsontherapie ViennaAustria
  • University of Graz (AT)
Corresponding author
Birkmayer, J. G. D.
Venue
Acta Neurologica Scandinavica
Publisher
Hindawi Limited
Published
1993-05
Volume
87
Issue
S146
Pages
32-35
ISSN
  • 0001-6314 (ISSN-L)
  • 1600-0404
DOI
10.1111/j.1600-0404.1993.tb00018.x
OpenAlex
W103598237
Cited by
94
References
10
Citations by year
2026: 2 · 2025: 3 · 2024: 3 · 2023: 3 · 2021: 4 · 2020: 4 · 2019: 5 · 2018: 3 · 2017: 3 · 2016: 2 · 2015: 2 · 2014: 9 · 2013: 2 · 2012: 4
FWCI
0.30
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Acta Neurologica Scandinavica (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
  • Life Sciences › Neuroscience › Neurology › Neurological Disorders and Treatments
Keywords
NADH, Parkinson's disease, NAD+, intravenous administration, oral administration, disability improvement, treatment response, disease duration, age
MeSH terms
Administration, Oral, Aged, Disability Evaluation, Dopamine, Female, Humans, Infusions, Intravenous, Male, NAD, Neurologic Examination, Parkinson Disease, Tyrosine 3-Monooxygenase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review